🏛️ Verified NIH Record • Updated 2026-07-02
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (NCT04898634)
A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).
Who can join: Review the eligibility criteria below.
Location: Columbia University Medical Center Herbert Irving Pavilion — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Columbia University Medical Center Herbert Irving Pavilion — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Washington — Seattle, Washington
- Peking University Third Hospital — Beijing,
- Chongqing University Cancer Hospital — Chongqing,
- Sun Yat Sen University Cancer Center — Guangzhou,
- First Affiliated Hospital Of Wenzhou Medical College — Wenzhou,
- Centre Leon Berard — Lyon,
- APHM Hopital Timone — Marseille,
- Institut Gustave Roussy — Villejuif,
- National Cancer Center Hospital East — Kashiwa,
- Yokohama City University Medical Center — Yokohama,
- Antoni van Leeuwenhoek — Amsterdam,
- Erasmus MC — Rotterdam,
- Hosp Univ Fund Jimenez Diaz — Madrid,
- Hosp Univ Hm Sanchinarro — Madrid,
- Hosp Virgen de La Victoria — Málaga,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostatic Neoplasms
- A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer — Phoenix, Arizona
- PSMA PET/CT for Assessment of Recurrent Prostate Cancer — Vancouver, British Columbia
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS — Homewood, Alabama
- A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer — Los Angeles, California
- Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy — Fort-de-France,
- A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer — Birmingham, Alabama
Explore by condition: All Prostatic Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.